CTTQ is a multinational pharmaceutical company with integrated R&D, manufacturing, marketing and distribution capabilities. It is the core enterprise of Sino Biopharmaceutical (01177.HK) and is well-known in the field of anti-tumor and liver disease in China. It is innovation driven and focus on R&D to develop new technologies and patented products to improve quality of life and promote human health. It was ranked 13th on the list of the “Top 100 Pharmaceutical Enterprises in China” in 2022 and is the best industrial enterprise in China's pharmaceutical R&D product line in 2023 (selected and released by China Pharmaceutical Industry Information Center).
At present, the company has 148 projects under R&D, including 80 innovative drugs, and has a total of 3080 valid patent applications with 1137 valid granted patents, forming a benign pattern of "sales generation, reserve generation and R&D generation".
CTTQ has six major R&D and production bases located in Nanjing, Lianyungang and Shanghai. It is the first company that obtained the new version of the Chinese GMP certificate. Multiple production lines of OSD and injectable products have obtained EU cGMP and US FDA certification.
CTTQ focuses on building product clusters in the fields of cancer, liver disease, and respiration, oriented by people's livelihood needs. In addition to the field of liver disease in which CTTQ take leading position, the company has formed a leading product line of innovative anti-tumor drugs represented by Anlotinib (FOCUS V®). CTTQ also has a rich generic product line in the field of hematologic tumors including decitabine (first generic in China), imatinib (first generic in China), dasatinib (first generic in China), bortezomib, lenalidomide etc. and abiraterone and gefitinib, etc. in the field of solid tumors. Respiration, antibiotics and other fields will also be the key direction of future development. CTTQ also has a complete biotechnology platform with rich product line. Adalimumab injection, bevacizumab injection, rituximab injection and trastuzumab for injection have been marketed.
In the international market, fulvestrant injection, fosaprepitant for injection and other products have won European and American market favor. In the future development, CTTQ will comprehensively promote the four major strategies of "organizational integration", "comprehensive innovation", "digitization" and "internationalization", while innovating technological paths and business models, and driving the transformation and upgrading of R&D, production technology and marketing mode, and move steadily towards an innovative and international pharmaceutical group.
